Melanoma neoantigen vaccines: Are we getting more personal now?
Détails
ID Serval
serval:BIB_362339C5E2F1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Melanoma neoantigen vaccines: Are we getting more personal now?
Périodique
Med
ISSN
2666-6340 (Electronic)
ISSN-L
2666-6340
Statut éditorial
Publié
Date de publication
12/04/2024
Peer-reviewed
Oui
Volume
5
Numéro
4
Pages
288-290
Langue
anglais
Notes
Publication types: Clinical Trial, Phase II ; Randomized Controlled Trial ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
KEYNOTE-942 <sup>1</sup> is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain.
Mots-clé
Humans, Melanoma, Cancer Vaccines/therapeutic use, Adjuvants, Immunologic, Adjuvants, Pharmaceutic, Skin Neoplasms
Pubmed
Création de la notice
19/04/2024 9:21
Dernière modification de la notice
20/04/2024 6:57
Données d'usage
